I'm going to speak to what I know, which is intellectual property. I'm not an economist; I'm a political scientist.
I'm going to actually say we don't need to be giving IP protection. In fact, I think if anything, we need to be rethinking the IP model. That is one of the major issues we have in terms of access to COVID-19 vaccines. We've seen that, historically, the United States is actually saying we should be waiving intellectual property rights.
I would say we need to be negotiating differently with the industry. These are different times and bigger crises, and the same old doesn't work. That doesn't quite directly answer your question, but I'm hoping—